TY - JOUR
T1 - Treatment of post-viral olfactory dysfunction
T2 - an evidence-based review with recommendations
AU - Hura, Nanki
AU - Xie, Deborah X.
AU - Choby, Garret W.
AU - Schlosser, Rodney J.
AU - Orlov, Cinthia P.
AU - Seal, Stella M.
AU - Rowan, Nicholas R.
N1 - Funding Information:
Funding sources for the study: RJS is a consultant for Stryker, Optinose, GSK, a medical director for Healthy Humming and has received grant support from Stryker, Optinose and Healthy Humming. GWC is a consultant for Tissium, LLC, and Intersect ENT, Inc.
Funding Information:
sources for the study: RJS is a consultant for Stryker, Optinose, GSK, a medical director for Healthy Humming and has received grant support from Stryker, Optinose and Healthy Humming. GWC is a consultant for Tissium, LLC, and Intersect ENT, Inc.
Publisher Copyright:
© 2020 ARS-AAOA, LLC
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Post-viral olfactory dysfunction (PVOD) is one of the most common causes of olfactory loss. Despite its prevalence, optimal treatment strategies remain unclear. This article provides a comprehensive review of PVOD treatment options and provides evidence-based recommendations for their use. Methods: A systematic review of the Medline, Embase, Cochrane, Web of Science, Scopus, and Google Scholar databases was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies with defined olfactory outcomes of patients treated for PVOD following medical, surgical, acupuncture, or olfactory training interventions were included. The Clinical Practice Guideline Development Manual and Conference on Guideline Standardization (COGS) instrument recommendations were followed in accordance with a previously described, rigorous, iterative process to create an evidence-based review with recommendations. Results: From 552 initial candidate articles, 36 studies with data for 2183 patients with PVOD were ultimately included. The most common method to assess olfactory outcomes was Sniffin’ Sticks. Broad treatment categories included: olfactory training, systemic steroids, topical therapies, a variety of heterogeneous non-steroidal oral medications, and acupuncture. Conclusion: Based on the available evidence, olfactory training is a recommendation for the treatment of PVOD. The use of short-term systemic and/or topical steroids is an option in select patients after careful consideration of potential risks of oral steroids. Though some pharmacological investigations offer promising preliminary results for systemic and topical medications alike, a paucity of high-quality studies limits the ability to make meaningful evidence-based recommendations for the use of these therapies for the treatment of PVOD.
AB - Background: Post-viral olfactory dysfunction (PVOD) is one of the most common causes of olfactory loss. Despite its prevalence, optimal treatment strategies remain unclear. This article provides a comprehensive review of PVOD treatment options and provides evidence-based recommendations for their use. Methods: A systematic review of the Medline, Embase, Cochrane, Web of Science, Scopus, and Google Scholar databases was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies with defined olfactory outcomes of patients treated for PVOD following medical, surgical, acupuncture, or olfactory training interventions were included. The Clinical Practice Guideline Development Manual and Conference on Guideline Standardization (COGS) instrument recommendations were followed in accordance with a previously described, rigorous, iterative process to create an evidence-based review with recommendations. Results: From 552 initial candidate articles, 36 studies with data for 2183 patients with PVOD were ultimately included. The most common method to assess olfactory outcomes was Sniffin’ Sticks. Broad treatment categories included: olfactory training, systemic steroids, topical therapies, a variety of heterogeneous non-steroidal oral medications, and acupuncture. Conclusion: Based on the available evidence, olfactory training is a recommendation for the treatment of PVOD. The use of short-term systemic and/or topical steroids is an option in select patients after careful consideration of potential risks of oral steroids. Though some pharmacological investigations offer promising preliminary results for systemic and topical medications alike, a paucity of high-quality studies limits the ability to make meaningful evidence-based recommendations for the use of these therapies for the treatment of PVOD.
KW - budesonide
KW - evidence-based medicine
KW - olfaction disorders
KW - olfactory training
KW - smell
KW - viral infection
UR - http://www.scopus.com/inward/record.url?scp=85087166782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087166782&partnerID=8YFLogxK
U2 - 10.1002/alr.22624
DO - 10.1002/alr.22624
M3 - Review article
C2 - 32567798
AN - SCOPUS:85087166782
SN - 2042-6976
VL - 10
SP - 1065
EP - 1086
JO - International Forum of Allergy and Rhinology
JF - International Forum of Allergy and Rhinology
IS - 9
ER -